| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/25/2010 | US20100047361 Active Principle which is capable of inducing the conversion of inactive TGFb-Latent into active TGFb |
| 02/25/2010 | US20100047356 Charge-assembled capsules for phototherapy |
| 02/25/2010 | US20100047354 Combretum laurifolium mart. extract and methods of extracting and using such extract |
| 02/25/2010 | US20100047314 Folinic acid derivatives for promoting bone growth |
| 02/25/2010 | US20100047307 Injectable drug carrier comprising layered double hydroxide |
| 02/25/2010 | US20100047289 Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization |
| 02/25/2010 | US20100047288 Hybrid cells for treating cancer patients |
| 02/25/2010 | US20100047285 Anticancer agents using verotoxin variants |
| 02/25/2010 | US20100047265 Active antiangiogenic therapy |
| 02/25/2010 | US20100047261 Base-modified rna for increasing the expression of a protein |
| 02/25/2010 | US20100047260 Methods and Compositions Relating To a Vaccine Against Prostate Cancer |
| 02/25/2010 | US20100047251 Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| 02/25/2010 | US20100047244 Human CTLA-4 Antibodies and Their Uses |
| 02/25/2010 | US20100047236 Antibody variants |
| 02/25/2010 | US20100047227 Novel anticancer cathepsin formulations and anticancer agent for use in combined anticancer therapy |
| 02/25/2010 | US20100047220 Substances |
| 02/25/2010 | US20100047215 Stem cell targeting methods |
| 02/25/2010 | US20100047208 Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof |
| 02/25/2010 | US20100047205 Vaccine immunotherapy |
| 02/25/2010 | US20100047178 Perylenequinone derivatives and uses thereof |
| 02/25/2010 | US20100047169 NK Cell Receptor Conjugates for Treating Malignancies |
| 02/25/2010 | US20100047166 Antibodies and related molecules that bind to 58p1d12 proteins |
| 02/25/2010 | US20100047163 Synthetic LDL as Targeted Drug Delivery Vehicle |
| 02/25/2010 | DE102008038222A1 Indazol-5-carbonsäurehydrazid-derivate Indazole-5-carboxylic acid derivatives |
| 02/25/2010 | DE102008038221A1 7-Azaindolderivate 7-azaindole derivatives |
| 02/25/2010 | DE102008038220A1 Oxadiazolderivate Oxadiazole |
| 02/25/2010 | DE102008002999A1 Composition, useful as anticancer or immunostimulants, cosmetics, preferably hair growth- and/or nail care products, dietary supplement and all-purpose cleaners and to treat e.g. gastric ulcers and cold, comprises ginger and chamomile |
| 02/25/2010 | DE102006053593B4 Verfahren zur Herstellung von Letrozol Process for the preparation of letrozole |
| 02/25/2010 | CA2735048A1 6-substituted 2-(benzimidazolyl)purine and purinone derivatives and 6-substituted 2-(imidazolo[4,5- c]pyridinyl)purine and purinone derivatives for immunosuppression |
| 02/25/2010 | CA2734892A1 Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase |
| 02/25/2010 | CA2734838A1 T cell receptors and related materials and methods of use |
| 02/25/2010 | CA2734828A1 Chemoprevention of head and neck squamous cell carcinomas |
| 02/25/2010 | CA2734809A1 Dabigatran in tumour therapy |
| 02/25/2010 | CA2734802A1 Pyrrolopyrimidine compounds as cdk inhibitors |
| 02/25/2010 | CA2734740A1 Engineered synergistic oncolytic viral symbiosis |
| 02/25/2010 | CA2734650A1 Organoarsenic compounds and methods for the treatment of cancer |
| 02/25/2010 | CA2734515A1 Inhbb epitope peptides and vaccines containing the same |
| 02/25/2010 | CA2734467A1 Hig2 and urlc10 epitope peptide and vaccines containing the same |
| 02/25/2010 | CA2734446A1 Methods and compositions for treatment of bone defects with placental cell populations |
| 02/25/2010 | CA2734325A1 Derivatives of apf and methods of use |
| 02/25/2010 | CA2734265A1 Dock-and-lock (dnl) vaccines for cancer therapy |
| 02/25/2010 | CA2733902A1 Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling |
| 02/25/2010 | CA2733790A1 Macrocyclic compounds for inhibition of tumor necrosis factor alpha |
| 02/25/2010 | CA2733688A1 New (poly)aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents |
| 02/25/2010 | CA2733554A1 Mif modulators |
| 02/25/2010 | CA2732969A1 Novel compounds and their uses in diagnosis |
| 02/25/2010 | CA2730357A1 Azaindole inhibitors of iap |
| 02/25/2010 | CA2728103A1 Small molecule inhibitors of n-terminus activation of the androgen receptor |
| 02/24/2010 | EP2157102A1 Antibodies against tenascin-C |
| 02/24/2010 | EP2157097A1 Specific binding agents of human angiopoietin-2 |
| 02/24/2010 | EP2157093A1 Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof |
| 02/24/2010 | EP2157089A1 The therapeutic uses of imidazol-5-carboxylic acid derivatives |
| 02/24/2010 | EP2157081A1 Indolinones substituted in six locations, their manufacture and their application as medicine |
| 02/24/2010 | EP2156832A1 Pharmaceutical composition |
| 02/24/2010 | EP2156189A1 Tnf gene expression as a biomarker of sensitivity to antagonists of inhibitor of apoptosis proteins |
| 02/24/2010 | EP2155877A2 Rna antagonist compounds for the modulation of her3 |
| 02/24/2010 | EP2155872A1 Tem8 peptides and vaccines comprising the same |
| 02/24/2010 | EP2155791A1 Humanized and chimeric anti-trop-2 antibodies that mediate cancer cell cytotoxicity |
| 02/24/2010 | EP2155786A2 Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label |
| 02/24/2010 | EP2155783A2 Cross-species-specific cd3-epsilon binding domain |
| 02/24/2010 | EP2155758A1 Tetrahydrofuro ý3 4-d¨dioxolane compounds for use in the treatment of viral infections and cancer |
| 02/24/2010 | EP2155753A1 Substituted imidazopyridazines as pi3k lipid kinase inhibitors |
| 02/24/2010 | EP2155742A1 5-aminopyrazol-3-yl-3h-imidazo [4,5-b]pyridine derivatives and their use for the treatment of cancer |
| 02/24/2010 | EP2155735A2 Triazolyl aminopyrimidine compounds |
| 02/24/2010 | EP2155734A2 Triazolyl aminopyrimidine compounds |
| 02/24/2010 | EP2155730A2 Aminopyrimidines useful as kinase inhibitors |
| 02/24/2010 | EP2155722A1 Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer |
| 02/24/2010 | EP2155698A1 Novel thermodynamically stable polymorphic form-l of letrozole |
| 02/24/2010 | EP2155682A2 Salts of isophosphoramide mustard and analogs thereof |
| 02/24/2010 | EP2155681A1 Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
| 02/24/2010 | EP2155677A1 Mono-hydrochloric salts of an inhibitor of histone deacetylase |
| 02/24/2010 | EP2155335A1 Pharmaceutical composition, use of the pharmaceutical composition for treating a brain tumor, production process thereof and a kit of parts comprising the pharmaceutical composition |
| 02/24/2010 | EP2155262A2 Compositions for targeted imaging and therapy |
| 02/24/2010 | EP2155255A2 Compositions that include a hydrophobic compound and a polyamino acid conjugate |
| 02/24/2010 | EP2155254A2 Polymers conjugated with platinum drugs |
| 02/24/2010 | EP2155253A2 Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs |
| 02/24/2010 | EP2155252A1 Injectable polymer-lipid blend for localized drug delivery |
| 02/24/2010 | EP2155250A1 Carbohydrate-containing pan cancer marker |
| 02/24/2010 | EP2155243A2 Compositions and methods comprising klk3, psca, or folh1 antigen |
| 02/24/2010 | EP2155237A2 Method for treatment of cancers or inflammatory diseases |
| 02/24/2010 | EP2155202A2 3,6-disubstituted-imidazo[1,2-b]pyridazines and 3,5-disubstituted pyrazolo[1,5-a]pyrimidines as phosphatidylinositol-3-kinase inhibitors |
| 02/24/2010 | EP2155198A2 Piperidine/piperazine derivatives |
| 02/24/2010 | EP2155194A1 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 02/24/2010 | EP2155193A1 Use of hdac inhibitors for the treatment of melanoma |
| 02/24/2010 | EP2155192A2 Tetrahydroisoquinolines as tumour growth inhibitors |
| 02/24/2010 | EP2155191A1 Transglutaminase inhibitor comprising egcg and a method for producing thereof |
| 02/24/2010 | EP2154971A2 A synergistic pharmaceutical combination for the treatment of cancer |
| 02/24/2010 | EP2154967A1 Pyrimidine derivatives |
| 02/24/2010 | EP2154963A1 Iminopyrrolidone thiol amino acid conjugates, pharmaceutical compositions and methods for the treatment of cancer |
| 02/24/2010 | EP2059520B1 1,4,5,6,7,8-hexahydro-i,2,5-triaza-azulene derivatives as orexin receptor antagonists |
| 02/24/2010 | EP1901750B1 Tumor treatment with gliotoxin derivatives |
| 02/24/2010 | EP1869185B1 Conjugate comprising p21 protein for the treatment of cancer |
| 02/24/2010 | EP1636225B1 Pyridino 1,2-a pyrimidin-4-one compounds as anticancer agents |
| 02/24/2010 | EP1572066B1 Novel method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within mmp-2 |
| 02/24/2010 | EP1553962B1 Combination chemotherapy with chlorotoxin |
| 02/24/2010 | EP1501774B9 Polyunsaturated linear aldehydes and their derivatives with anti-radical activity |
| 02/24/2010 | EP1465631B1 Pyrimidine a2b selective antagonist compounds, their synthesis and use |
| 02/24/2010 | EP1290011B1 Melphalan derivatives and their use as cancer chemotherapeutic drugs |
| 02/24/2010 | EP1200607B1 Tet repressor-based transcriptional regulatory proteins |
| 02/24/2010 | EP1033979B2 Combination of cyp2a6 enzyme inhibitors and nicotine and their therapeutic use |